Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Cempra To Present Full Data Set Of Phase 2 Clinical Trial Of CEM-101

3/31/2012 1:33 AM ET

Cempra Inc. (CEMP: Quote) said that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases or ECCMID, in London, demonstrating CEM-101's efficacy to be comparable to levofloxacin in a Phase 2 trial of patients with community-acquired bacterial infections or CABP.

The phase 2 clinical trial of the study also showcases olithromycin's favorable safety and tolerability profile compared to levofloxacin, the company added.

Solithromycin is the first fluoroketolide with a number of attributes that may provide clinically important advantages over several comparator products.

Prabhavathi Fernandes, chief executive officer of Cempra commented "This is the first time that the full data set of this Phase 2 trial has been available for review by the infectious disease community. The promising results of this clinical trial will now be the basis for the initiation of our Phase 3 program in CABP. We expect to begin the first Phase 3 trial evaluating oral solithromycin in moderate-to-moderately severe CABP patients in the second half of 2012."

The CEO stated " Additionally, we are planning Phase 3 trials for 2013 testing the efficacy of intravenous-to-oral step down administration of solithromycin in moderate-to-severe CABP."

In a separate press release, the clinical-stage pharmaceutical company noted that data will be presented at the ECCMID demonstrating that CEM-101 (solithromycin) would be active against antibiotic-resistant strains of N. gonorrhoeae.

Magnus Unemo, associate professor, National Reference Laboratory for Pathogenic Neisseria said "In vitro studies, including the presentation at ECCMID, have indicated that solithromycin can be a promising agent for treating patients with gonococcal infections. N. gonorrhoeae is becoming a serious public health problem because current antibiotic options are gradually becoming less effective in treating the disease. New options are required and solithromycin appears to be a promising candidate."

Register
To receive FREE breaking news email alerts for Cempra, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Chipmaker Advanced Micro Devices Inc. said Thursday after the markets closed that its first quarter loss narrowed from last year, helped by strong revenue growth in its graphics and visual solutions business. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue. After trending higher over the past few sessions, stocks showed a lack of direction throughout the trading day on Thursday. The major averages spent the session bouncing back and forth across the unchanged line before ending the day mixed. While the major averages closed on opposite sides of the unchanged line, they all showed only modest moves. U.S. Secretary Of State John Kerry said Thursday that he and his counterparts from Russia, Ukraine and the European Union have reached an agreement on a preliminary plan for ending the ongoing crisis in Ukraine. Kerry was speaking at the end of the Ukraine contact group's first meeting, comprising the foreign ministers of Russia, Ukraine, the EU and the U.S., in the Swiss city of Geneva.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.